# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target ...
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate o...